ADMA Biologics, Inc.
ADMA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $4,398 | $4,717 | $4,055 |
| - Cash | $61 | $90 | $72 | $103 |
| + Debt | $79 | $84 | $82 | $82 |
| Enterprise Value | – | $4,391 | $4,728 | $4,034 |
| Revenue | $134 | $122 | $115 | $118 |
| % Growth | 10% | 6.3% | -2.3% | – |
| Gross Profit | $76 | $67 | $61 | $63 |
| % Margin | 56.3% | 55.1% | 53.2% | 53.9% |
| EBITDA | $51 | $44 | $37 | $40 |
| % Margin | 38.2% | 36.1% | 32.6% | 33.6% |
| Net Income | $36 | $34 | $27 | $112 |
| % Margin | 27.1% | 28.1% | 23.4% | 95.2% |
| EPS Diluted | 0.15 | 0.14 | 0.11 | 0.46 |
| % Growth | 7.1% | 27.3% | -76.1% | – |
| Operating Cash Flow | $13 | $21 | -$20 | $50 |
| Capital Expenditures | -$14 | -$2 | -$5 | -$3 |
| Free Cash Flow | -$1 | $19 | -$24 | $47 |